Volitionrx Net Worth
Volitionrx Net Worth Breakdown | VNRX |
Volitionrx Net Worth Analysis
Volitionrx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Volitionrx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Volitionrx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Volitionrx's net worth analysis. One common approach is to calculate Volitionrx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Volitionrx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Volitionrx's net worth. This approach calculates the present value of Volitionrx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Volitionrx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Volitionrx's net worth. This involves comparing Volitionrx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Volitionrx's net worth relative to its peers.
Enterprise Value |
|
To determine if Volitionrx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Volitionrx's net worth research are outlined below:
| Volitionrx is way too risky over 90 days horizon | |
| Volitionrx has some characteristics of a very speculative penny stock | |
| Volitionrx appears to be risky and price may revert if volatility continues | |
| Volitionrx has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.23 M. Net Loss for the year was (27.26 M) with profit before overhead, payroll, taxes, and interest of 1.31 M. | |
| Volitionrx currently holds about 16.42 M in cash with (25.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. | |
| Volitionrx has a frail financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: What drives VolitionRx Limited stock price - Powerful profit generation - Jammu Links News |
Volitionrx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Volitionrx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Volitionrx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Volitionrx's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 70.19 M.Market Cap |
|
Project Volitionrx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.97) | (3.12) | |
| Return On Capital Employed | (16.80) | (15.96) | |
| Return On Assets | (2.87) | (3.01) | |
| Return On Equity | 1.08 | 1.14 |
When accessing Volitionrx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Volitionrx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Volitionrx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Volitionrx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Volitionrx. Check Volitionrx's Beneish M Score to see the likelihood of Volitionrx's management manipulating its earnings.
Evaluate Volitionrx's management efficiency
Volitionrx has return on total asset (ROA) of (1.0804) % which means that it has lost $1.0804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3006) %, meaning that it created substantial loss on money invested by shareholders. Volitionrx's management efficiency ratios could be used to measure how well Volitionrx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.14 in 2025, whereas Return On Tangible Assets are likely to drop (3.12) in 2025. At this time, Volitionrx's Total Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 484.2 K in 2025, whereas Total Current Assets are likely to drop slightly above 3.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.30) | (0.29) | |
| Tangible Book Value Per Share | (0.31) | (0.29) | |
| Enterprise Value Over EBITDA | (2.13) | (2.23) | |
| Price Book Value Ratio | (2.08) | (2.19) | |
| Enterprise Value Multiple | (2.13) | (2.23) | |
| Price Fair Value | (2.08) | (2.19) | |
| Enterprise Value | 54.5 M | 66.5 M |
The strategic initiatives led by Volitionrx's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 59.7497 | Revenue | Quarterly Revenue Growth 0.436 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Volitionrx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Volitionrx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Volitionrx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Volitionrx time-series forecasting models is one of many Volitionrx's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Volitionrx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Volitionrx Earnings per Share Projection vs Actual
Volitionrx Corporate Management
| Salvatore DVM | Chief LLC | Profile | |
| Scott Powell | Executive Relations | Profile | |
| Gael MBA | Chief Officer | Profile | |
| Gaetan Michel | Chief Officer | Profile | |
| Louise Day | Chief Officer | Profile | |
| Jacob MBA | Chief Officer | Profile |
Additional Tools for Volitionrx Stock Analysis
When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.